A new gold standard
Upstream’s lead diagnostic test, UARatio (based on BNPsp) will be used to screen patients entering the Emergency Department (ED) with chest pain. UARatio enables the identification of patients with unstable angina (UA). UA is a life threatening condition that can lead to heart attack.
UARatio has a negative predictive value (npv) of 98.4%, it is therefore a highly accurate screening tool for ruling out unstable angina. Ideally, for best clinical results, the test should be performed within 90 minutes of presentation at the ED. Upstream anticipates that its test will be run alongside Troponin. Troponin is the gold standard biomarker test for diagnosing heart attack. In using the two tests the Emergency Physician will be able to not only diagnose heart attack but also identify those AT RISK of heart attack. Currently it is difficult to diagnose AT RISK patients. With UARatio diagnosis is possible from a single rapid blood test.
Improving outcomes across ED
Rapid and early accurate diagnosis in an acute care setting such as the hospital ED improves patient outcomes, including reduced recovery times and more effectively utilises the finite resources within the ED. This provides flow on effects for better outcomes for a wide range of patients presenting to the ED, not just heart disease patients.
Meeting growing demand
The aging population globally expects to live longer than previous generations and also demands a high standard of medical care. These two factors place unprecedented demand on the ED. Fast, accurate diagnostic tools are an important way to help the ED meet this demand.
Rapid, early diagnoses with biomarkers
A suite of novel biomarkers provides the basis for offering earlier and specific diagnosis of heart disease and associated medical complications. Earlier diagnosis employing these biomarkers will result in improved patient recovery through faster recovery time, reduced rehospitalisation and more efficient use of emergency department resources.
The path to success
Our product development strategy involves making tests available directly for early adopters and key opinion leaders under a Research Use Only label and then conducting multicentre international trials to obtain regulatory approval prior to licensing to an international partner.